Form 4: Kiniksa Pharmaceuticals CFO Mark Ragosa Reports Stock Transactions

Chief Financial Officer Mark Ragosa of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares and Restricted Share Units.

Summary

• Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, filed a Form 4 detailing changes in beneficial ownership.
• On April 7, 2025, Ragosa acquired 2,694 Class A Ordinary Shares through the vesting of Restricted Share Units (RSUs).
• Also on April 7, 2025, Ragosa disposed of 1,303 Class A Ordinary Shares at a price of $20.28.
• Following these transactions, Ragosa directly owns 26,498 Class A Ordinary Shares.
• Ragosa also directly owns 2,694 Restricted Share Units.
• The RSUs vest over a four-year period, with 25% vesting annually from April 7, 2022.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a key executive.

Key Dates

Keywords

Form 4, Kiniksa Pharmaceuticals, Mark Ragosa, CFO, Stock Transaction, Beneficial Ownership, KNSA, Restricted Share Units, Class A Ordinary Shares